key: cord-0822123-q55b9ygl
authors: Farhat Ullah, Muhammad; Ali, Yasir; Ramzan Khan, Muhammad; Ullah Khan, Inam; Yan, Bing; Ijaz Khan, M.; Malik, M. Y.
title: A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease
date: 2021-10-13
journal: Saudi J Biol Sci
DOI: 10.1016/j.sjbs.2021.10.020
sha: 86187e442d4b1fd936b48685393344300db0e27a
doc_id: 822123
cord_uid: q55b9ygl

The new coronavirus SARS-CoV-2 pandemic has put the world on lockdown for the first time in decades. This has wreaked havoc on the global economy, put additional burden on local and global public health resources, and, most importantly, jeopardised human health. CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, and the CRISPR associated (Cas) protein (CRISPR/Cas) was identified to have structures in E. coli. The most modern of these systems is CRISPR/Cas. Editing the genomes of plants and animals took several years and cost hundreds of thousands of dollars until the CRISPR approach was discovered in 2012. As a result, CRISPR/Cas has piqued the scientific community's attention, particularly for disease diagnosis and treatment, because it is faster, less expensive, and more precise than previous genome editing technologies. Data from gene mutations in specific patients gathered using CRISPR/Cas can aid in the identification of the best treatment strategy for each patient, as well as other research domains such as coronavirus replication in cell culture, such as SARS-CoV2. The implications of the most prevalent driver mutations, on the other hand, are often unknown, making treatment interpretation difficult. For detecting a wide range of target genes, the CRISPR/Cas categories provide highly sensitive and selective tools. Genome-wide association studies are a relatively new strategy to discovering genes involved in human disease when it comes to the next steps in genomic research. Furthermore, CRISPR/Cas provides a method for modifying non-coding portions of the genome, which will help advance whole genome libraries by speeding up the analysis of these poorly defined parts of the genome.

allowed precise changes to be performed in a variety of genomes, including dsDNA viral genomes (gRNA) Because gRNAtargeted Cas generates a DSB in the genome, two primary repair pathways compete to fix it, causing some sequence alterations ( 

CRISPR/Cas systems are divided into two categories: those that use multi-protein effector complexes and those that use single-protein effectors. Class 1 is made up of types I, III, and IV, whereas class 2 is made up of types II, V, and VI. It can also be divided into 19 different subtypes, with more CRISPR/Cas systems likely in the future. A type II single-protein effector derived from Streptococcus pyogenes is the most commonly utilised corporate Cas protein for functional broadcast (SpCas9). It's a type of guide RNA that helps the target gene get cleaved (Ford K et al., 2019) . Because type I and III CRISPR/Cas systems have several Cas proteins, whereas type II CRISPR/Cas systems only have the Cas9 protein, this result was reached (Makarova K.S et al., 2011 ).

In the last few centuries, World has been hit hard by significant challenges like diseases and hunger. Humans continued to put efforts to get rid of the diseases and fulfill the needs of food security. Although many advancements have been made, with several milestones being achieved, the available technologies are still facing many difficulties in controlling diseases and better food security. In the past, many technologies provided rays of hope but soon vanished with a lot of loopholes. However, in recent times, the CRISPR technology implementation enhances the hopes of many solutions and challenges regarding disorders and scarcity of food (Ogaugwu C.E et al., 2019) . A different human cell has been cultured in the modified medium of Dulbecco Eagle such as immortalized MRC5-hTERT fibroblast with supplementation of 4.5g/L glucose 1% penicillinstreptomycin, and fetal bovine serum (King M.W and J. Munger, 2019).

TALEN, Case9, and ZFN, like engineered nucleases, actively participate in modifications by breaking double-stranded DNA in specific genomic loci, which is then repaired by one of at least two cellular DNA modifications pathways, namely homology-directed repair (HDR) and nonhomologous end-joining (NHEJ). In the last two decades, the discovery of transcription activators like effectors (TALEs) and programmable DNA binding proteins such as Zinc fingers (ZFs) resulted in the successful development of genome modifying equipment. Zfs are Cys2-His (C2H2) rich sequences, unlike DNA binding domains that are acquired from a transcription factor's family of Eukaryotes (Rahman S et al., 2019) . In prokaryotic cells, adaptive immune response exists in Cas9 proteins that inspired CRISPR genome-editing technology. CRISPR-Cas9 genome editing technology is more advanced and efficient compared to conventional genome-editing technologies. Besides the simplicity and efficiency in target designing and regulation, it can target multiple genes at the same time.

Small guided RNA (sgRNA) and Cas proteins are the two significant components of CRISPR. The sequence in sgRNA is also sometimes referred to as the scaffold. sgRNA contains target-specific spacer sequences and Cas enzyme attachment site. These sequences are concurrently crowded with 20 nucleotides, protospacer adjacent motif (PAM), Cas9 target sequence and a short DNA sequence of 2-6 base pairs, respectively. The Cas9 enzyme specifies the length of the PAM sequence (Kaushik I et 

The efficiency of the editing techniques majorly drives the difficulties in genome editing. Advance genome editing technologies have minimized the errors with improvements in genome editing's therapeutic efficacy by improving the editing rate. The double-stand break restoration pathways in CRISPR-Cas systems act as regulatory components that significantly increase the editing rate. The editing efficiency among different cellular states and types vary due to the difference in endogenous cellular DNA repair mechanisms based on HDR and NHEJ. The mechanism of activation in end-joining (NHEJ) and homology-directed repair is different in the whole cell cycle, NHEJ being active in the whole-cell cycle, makes it more efficient in knocking out carcinogenic genes and generating indels, unlike the operation of HDR that varies in different cell cycle phases like S/G2. The HDR efficiency is DNA template type and homology arm length-dependent and more precisely, is relatively slow. HDR is based on the single-strand oligonucleotides or a plasmid containing alleles, and the transformation of the HDR template depends on the viral and non-viral vectors (Chen M et al., 2019).

Commercial and Academic institutes around the World have made an available variety of CRISPR resources and online tools. Table 1 reflects the number of widely utilized resources with its URL, including more detailed documentation of all the resources. These CRISPR resources play an unprecedented role in identifying and recognizing the suitable gRNA, listing detailed information for the selection of gRNAs for experimental purposes. Some tools help mention gRNA for specific practical applications, while others count it as a part of the whole experimental design, starting with target location identification (Thomas M et al., 2019) . 

CRISPR/Cas9 technology is currently more widely implemented in many fields, including food / 

Moral assessments in biomedicine are majorly driven by the potential risks, benefits, and attempts 

Even with the fast growth of the COVID-19 epidemic, inopportunely, antivirals otherwise additional drugs silent are until now toward remaining accepted intended for the COVID-19

treatment. Though the abrupt epidemic has required repurposing the previously nearby medications (designated in Fig. 3 ), they consume remained standards of preserving action in contradiction of HIV, MERS, and SARSCOV-1.

The usage of an existing anti-virus can be a lifesaver when it comes to reducing viral load and 

Based on its low EC50, 1.13 M, chloroquine, a long-used antimalarial and anti-rheumatic drug, has been discovered to have strong anti-COVID-19 action (Wang M et al., 2020) . The fact that chloroquine had good in vitro results encouraged scientists to give it to the human subjects in his studies. Since his low EC50 also advanced cytotoxic meditation CC50, chloroquine has been widely used in human clinical trials at more than ten Chinese hospitals. The outcomes in terms of viral weight loss, illness duration, and COVID-19 pneumonia exacerbation have yet to be determined (Gao J et al., 2020) . Chloroquine's capacity to prevent the virus from joining and entering the patient cell is the only probable mechanism for its anti-COVID-19 properties. 

A randоmized CONTROLLED OPEN LABEL study was done in China 

The 

Because of the rising range of COVID-19 contamination around the world, now is the moment to Inappropriately, there is still a scarcity of data, studies, and trials that have advanced drugs in violation of COVID-19. Arbidol (umifenovir), a different chemical, is nonetheless thought to impede COVID-19 endocytosis in the host cell. This is why, despite the COVID-19, Arbidol is still being studied in several research trials (Liu C et al., 2020) . The Chinese scientific trial of activities laterally by the NIH is leading trials on the efficacy of Arbidol, and is also alone otherwise by the protease inhibitor favipiravir (NCT04260594, ChiCTR2000030254) (Chen C et al., 2020) . The needed of the SARS-CoV-2 spike protein is resolved by ACE2 parenteral management, which is shadowed by the reserve of cellular endocytosis (Kuba K et al., 2005) . This push would result in a significant improvement in the lung cellular wound. These encouraging findings of human recombinant ACE2 (APN01) were assessed to be crucial to a projected decrease in AN-II-mediated lung damage and IL-6 stages. That idea was still plenty to take care of a RhACE2 scientific experiment. Peiron Biologics is currently sponsoring scientific research on the efficacy and also care of the APN01, which is still in stage II (NCT04335136) (NIH, 2020). 

Symptomatic patients with mild COVID-19 (fever> 37.5°C, fatigue, but no breathing difficulties)

should isolate suspected confirmed cases in the quarantine area. In addition, symptomatic relief is recommended. Fever is typically treated with paracetamol and/or nonsteroidal anti-inflammatory drugs, and there is no specific treatment at this time. Furthermore, Chinese doctors and health professionals advise patients to use Chinese medicine to treat their illnesses .

European guidelines, on the other hand, have confirmed the use of hydroxychloroquine (HCQ) in COVID-19 patients. More information can be found in Table IV . (Nicastri E et al., 2020 ).

Increased breathing rate, lung ventilation, and active symptomatic therapy should be explored for individuals with cough and fever. In this case, broad-spectrum antibiotics should be considered to prevent opportunistic lung infections and proper oral hydration use. In order to reduce pulmonary secretions, it is recommended that the Chinese study also use selective M3 blockers. Furthermore, if antimalarials are contraindicated, anti-COVID-19 norms treatment with lopinavir or ritonavir is 

Better patients' plasma contains immunoglobulins that can be used to treat individuals with dynamic viral disease. In 2014, the National Institutes of Health (NIH) continued to fund scientific experiments to calculate recovering plasma treatment in the face of MERS-COV-induced ARDS.

The scientific trial was discontinued at stage II (NCT02190799) despite the fact that the results were still inadequate (NIH, 2020). This method of treatment has also been tested in the case of the Ebola virus in Africa. Furthermore, based on knowledge of immunoglobulin responses gained over the last two years from trials aimed at developing viral respiratory illnesses. The FDA uses recently accepted scientific tests to assess the efficacy and safety of this treatment technique in the current ailment. Recently, a randomised scientific trial was approved to evaluate the benefits of convalescent plasma in COVID-19 individuals who were censoriously ill; also, they looked with repercussions to show slightly otherwise no development. Furthermore, the disease time does not appear to be summarised by adding COVID-19 to the normal treatment (Li L et al., 2020) .

However, there are still hazards connected with immunoglobulin treatment, which is why,

This virus is particularly contagious due to its high level of person-to-person transmission.

Preventive defence trials and the use of a vaccination are the two most effective habits for reducing the spread of an epidemic. After our review's main worry, vaccination remains the backbone for the inhibition of slightly viral epidemic disease. Maximum basically, the vaccine must be essential to remove the high spreadability of COVID-19, which uncertainty not measured will remain to determine the present epidemic. The spike (S) protein linked to COVID-19's membrane is the most commonly chosen target for advancing a COVID-19 vaccine (Liu C et al., 2020) . In defiance of COVID-19, a variety of stages are currently used in vaccine research. Table V lists key COVID-19 pipeline vaccine developments around the world. NIH currently lists six immunisation trials, with the majority of them taking place in the United States, the United Kingdom, and China.

Based on the current assessment and evaluating literature inquiry, we can accelerate the most critical factors of CRISPR RNAs (crRNAs) and CASE protein effector. CRISPR will be a highly fundamental, dicisive, and vital research point for disease diagnosis and treatment in the future, with enormous potential for scientific research. Apart from that, it will be crucial in preventing gene and genetiс mutations, as well as transmissible diseases; it will also be necessary for viral tolerance to repair immune cells that fail to recognise, resulting in immune system failure. Prompt identification and quick care of this lethal disease are critical and required measures when using COVID-19 epedemic. The current primary diagnostic procedure has various drawbacks, including lack of durability and lengthy processes. Sunstitute nucleic acid recognition capabilities, such as reverse transcriptase-mediated isothermal amplification (RT-LAMP) and CRISPR, as well as immunoassay-based devices, are presently in the patenting stage. In accumulation, there is аn imperative need fоr drug improvment tо switch this lethal, worldwide eрidemiс, which is precarious for the wole international coomunity. The high mortality rate and spread of COVID-19

necessitate the use of appropriate medications and vaccines as critical tools in preventing the disease's spread. Several оrgаnizаtiоns with аpрrоved indiсаtоrs are currently being tested for COVID-19 treatment. Despite the fact that there has been insufficient progress in this area, treatment with remdesivir and dexаmethаsone has resulted in a promising response to саutiоn. In addition, cliniсаl trials are still being carried out on a number of medications. In addition, six vaccines are now being tested in clinics on an experimental basis, but recommending and selling safe and effective vaccines will take a year or more.

Administration USFD. Investigational COVID-19 convalescent plasma -emergency INDs

CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis. Emerging microbes & infections

Serum Institute of India brings Covid-19 vaccine into animal testing

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

The Middle East Respiratory Syndrome (MERS)

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health and quality of life outcomes

Remdesivir for the treatment of Covid19-preliminary report

Advances in respiratory virus therapeutics-A meeting report from the 6th isirv Antiviral Group conference

CRISPR ethics: moral considerations for applications of a powerful tool

Do CRISPR germline ethics statements cut it? The CRISPR journal

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Human coronavirus NL63 replication is cyclophilin Adependent and inhibited by nonimmunosuppressive cyclosporine A-derivatives including Alisporivir

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. in Seminars in immunopathology

Favipiravir versus Arbidol for COVID-19: a randomized clinical trial

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer letters

Thalidomide against coronavirus disease 2019 (COVID-19): a medicine with a thousand faces

Alisporivir inhibits MERS-and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model

Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture

Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis

Cyclosporin A inhibits the replication of diverse coronaviruses

Host factors in coronavirus replication, in Roles of Host Gene and Non-coding RNA Expression in Virus Infection

Immunoinformatics based prediction of recombinant multiepitope vaccine for the control and prevention of SARS-CoV-2

Phage response to CRISPR-encoded resistance in Streptococcus thermophilus

Early short course corticosteroids in hospitalized patients with COVID-19. medRxiv

Functional genomics via CRISPR-Cas

Clinical applications of CRISPR based genome editing and diagnostics

Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9

Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Nidovirales: Evolving the largest RNA virus genome

RNA replication of mouse hepatitis virus takes place at doublemembrane vesicles

Visualizing coronavirus RNA synthesis in time by using click chemistry

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

Avoiding the off-target effects of CRISPR/cas9 system is still a challenging accomplishment for genetic transformation

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv

Characterization and repurposing of type I and type II CRISPR-Cas systems in bacteria

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The role of immunophilins in viral infection

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features

Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia

CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment

Bevacizumab: a review of its use in advanced cancer

The CRISPR/Cas genome-editing tool: application in improvement of crops. Frontiers in plant science

Porcine epidemic diarrhea virus induces caspase-independent apoptosis through activation of mitochondrial apoptosis-inducing factor

Editing the human cytomegalovirus genome with the CRISPR/Cas9 system

Ultrastructural characterization of arterivirus replication structures: reshaping the endoplasmic reticulum to accommodate viral RNA synthesis

Can steroids reverse the severe COVID-19 induced 'cytokine storm

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Coronavirus infections and immune responses

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

Thalidomide and its analogues: a review of the potential for immunomodulation of fibrosis diseases and opthalmopathy

Infectious bronchitis virus generates spherules from zippered endoplasmic reticulum membranes

Evolution and classification of the CRISPR-Cas systems

Pulmonary thrombosis in 2019-nCoV pneumonia?

Natalizumab: a review of its use in the management of relapsingremitting multiple sclerosis

Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Mosaicism in CRISPR/Cas9-mediated genome editing

A randomized, controlled trial of Ebola virus disease therapeutics

Cyclophilin inhibition as potential therapy for liver diseases

Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes. PLoS pathogens

The long term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management

Cyclophilin A: a key player for human disease

A randomized trial of anticoagulation strategies in COVID-19

NIH. A study of a candidate COVID-19 vaccine (COV001)

Accessed 27

Bevacizumab in severe or critical patients with COVID-19 pneumonia (BEST-CP)

Clinical study of Arbidol hydrochloride tablets in the treatment of pneumonia caused by novel coronavirus

Accessed 4

Efficacy and Safety of hydroxychloroquine for treatment of pneumonia caused by 2019-nCoV ( HC-nCoV )

Accessed 4

Efficacy and safety of IFN-α2β in the treatment of novel coronavirus patients

Evaluation of the efficacy and safety of sarilumab in hospitalized patients With COVID-19

COVID-19

Immunity and safety of Covid-19 synthetic minigene vaccine

Accessed 8

Phase I clinical trial of a COVID-19 vaccine in 18-60 healthy adults (CTCOVID-19

Protective effect of aspirin on COVID-19 patients (PEAC)

Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis SARS CoV-2 infection

Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19)

Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19

tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers

Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19)

The clinical study of carrimycin on treatment patients with COVID-19

The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID-19) pneumonia

The National Institutes of Health COVID-19 Treatment Guidelines Panel provides recommendations for dexamethasone in patients with COVID-19

DexamethasoneforCOVID-19relatedARDS:amulticenter, randomized clinical trial

Genome editing in the mammalian brain using the CRISPR-Cas system

CRISPR in sub-Saharan Africa: applications and education

Novel Coronavirus (2019-nCoV): situation report

CRISPR diagnostics: Underappreciated uses in perinatology. in Seminars in perinatology

Open Reading Frame 1a-Encoded Subunits of the Arterivirus Replicase Induce Endoplasmic ReticulumDerived Double-Membrane Vesicles Which Carry the Viral Replication Complex

Safe CRISPR: Challenges and Possible Solutions

Analysis of CRISPR/Cas system of Proteus and the factors affected the functional mechanism. Life sciences

CoV-2 and coronavirus disease 2019: what we know so far

CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases. in Seminars in cell & developmental biology

Accessed4April2020. 105. Registry CCT. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia

Registry CCT. A randomized, double-blind, placebo parallelcontrolled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine

A randomized, open-label study to evaluate the efficacy and safety of lopinavir-ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)

Registry CCT. Comparative effectiveness and safety of ribavirin plus interferonalpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia

Registry CCT. Favipiravir combined with tocilizumab in the treatment of novel coronavirus pneumonia (COVID-19)-a multicenter, randomized

Accessed 4 april 2020. 110. Registry CCT. Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia

Registry CCT. The efficacy and safety of favipiravir for novel coronavirusinfected pneumonia: a multicenter, randomized, open, positive, parallel-controlled clinical study

Accessed 27

Harnessing CRISPR/Cas9 technology in cardiovascular disease

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Effects of chloroquine on viral infections: an old drug against today's diseases

Genome-scale CRISPR-Cas9 knockout screening in human cells

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Arterivirus molecular biology and pathogenesis

CRISPR-Cas biology and its application to infectious diseases

Ethics and germline gene editing

Suppression of feline coronavirus replication in vitro by cyclosporin A. Veterinary Research

Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B

Best practice for CRISPR design using current tools and resources

Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus

Complexes Are Membrane-Protected and Need a Host Factor for Activity In Vitro

Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

Tissue plasminogen activator (tpa) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

The advances in CRISPR technology and 3D genome. in Seminars in cell & developmental biology

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

In vivo cell type-specific CRISPR gene editing for sleep research

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

CRISPR/Cas9 for cancer research and therapy. in Seminars in cancer biology

Recent Progress in Studies of Arterivirusand Coronavirus-Host Interactions. Viruses

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-2020

Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections

Reducing mortality from 2019-nCoV: host-directed therapies should be an option. The Lancet